Clinical Trials
10 trialsNCT02465060 2026-06-03
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05308446 2026-06-03
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03190941 2026-05-29
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT04751370 2026-05-29
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03745326 2026-05-19
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT04432597 2026-05-18
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT04929028 2026-05-13
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01696981 2026-04-30
Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)
National Cancer Institute (NCI)
Phase NA Active not recruiting
NCT02381561 2026-04-13
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04287868 2026-04-13
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting